Biotech Values

[DewDiligence]

I am starting to think that a lovenox reversal agent will garner a moderate amount of sales. I have had to cancel numerous invasive procedures due to the patient being on lovenox. This has led to patients staying in the hospital longer than need be. It seems every patient in the hospital goes on at least mini dose lovenox for DVT prophylaxis.

Thanks for weighing in. Are you saying that Lovenox use in this setting has increased, or rather that your awareness of Lovenox use in this setting has increased? Also, can you quantify what you mean by “mini dose Lovenox” in this context? Does the word mini as you’re using it refer to duration, or to the size of the doses? T.i.a.

UFH [reversal]—I'm not convinced as protamine is so cheap. Unless you give it rapidly the minor complication rate is very small. (Transient drop in blood pressure).

We’re on the same wavelength. I think some posters on this board have been hoodwinked about the market potential for UFH reversal. Regards, Dew